NCT02739997View on ClinicalTrials.gov

Study of Ceftolozane/Tazobactam (MK-7625A) in Combination With Metronidazole in Japanese Participants With Complicated Intra-abdominal Infection (MK-7625A-013)

PHASE3CompletedINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

April 8, 2016

Primary Completion Date

July 28, 2017

Study Completion Date

July 28, 2017

Conditions

Intra-abdominal InfectionComplicated Intra-abdominal Infection

Interventions

DRUG

MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g)

MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) administered as an intravenous (IV) infusion

DRUG

metronidazole 500 mg

metronidazole 500 mg administered as an IV infusion

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02739997 - Study of Ceftolozane/Tazobactam (MK-7625A) in Combination With Metronidazole in Japanese Participants With Complicated Intra-abdominal Infection (MK-7625A-013) | Biotech Hunter | Biotech Hunter